Macrophage targeted delivery carrier as well as preparation and application thereof
By using amide-bonded chemokine MCP-1 polypeptide and Pluronic F127 in macrophage targeted delivery vectors, the problem of side effects and insufficient targeting of traditional chemotherapeutic drugs in tumor treatment is solved, and efficient tumors are achieved Drug delivery and therapeutic effects.
Patent Information
- Application Number
- CN202411217603.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Traditional chemotherapy drugs have problems of strong toxic side effects and recurrence in tumor treatment, and the existing nanoparticle drug-loading system is easily immune cleared in the blood circulation, lacks specific targeting of tumors, and is limited in spread, making it difficult to achieve efficient tumors. treat.
Develop a targeted delivery vector based on macrophages to couple the chemokine MCP-1 polypeptide with polyoxyethylene polyoxypropylene ether block copolymer Pluronic F127 through amide bonds to form targeted nanoparticles, using macrophages tumor homing properties are used for drug delivery.
It realizes efficient targeted delivery of drugs to the tumor site, reduces toxic and side effects, enhances the tumor treatment effect, significantly improves the biocompatibility and stability of anti-tumor drugs, and can respond and target tumor areas in the tumor microenvironment.
Smart Images

Figure CN119055786A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an anti-tumor drug targeted delivery carrier and its preparation and application, and in particular to a macrophage-based targeted delivery carrier and its preparation and application. Background Art
[0002] Traditional chemotherapy is currently one of the main means of treating tumors, but it has strong toxic side effects and is prone to recurrence. Nanoparticle (NP)-based drug delivery systems can effectively increase the accumulation of drugs in tumor sites to reduce toxic side effects, and have become an effective strategy to improve the efficacy of cancer treatment. However, the nanoparticles reported so far cannot be converted into better therapeutic effects in clinical trials because they are quickly cleared by the immune system in the blood circulation, lack specific targeted tumors, and their diffusion in tumor tissues is also limited. Therefore, it is necessary to develop efficient active targeted nano drug delivery systems. Active targeted drug delivery systems developed using the tumor homing characteristics and biocompatibility of endogenous cells such as macrophages (MA) have become a new strategy to solve the problems of traditional drug delivery systems in tumor treatment. Summary of the invention
[0003] Purpose of the invention: The purpose of the present invention is to provide a macrophage targeted delivery vector to solve the problem of how to deliver drugs to macrophages. Another purpose of the present invention is to propose a method for preparing a macrophage targeted delivery vector to solve the problem of how to prepare a macrophage targeted delivery vector. The third purpose of the present invention is to propose an application of a macrophage targeted delivery vector in the preparation of anti-tumor targeted drugs to solve the problem of how to prepare anti-tumor targeted drugs.
[0004] Technical solution: The macrophage targeted delivery carrier described in the present invention includes a chemokine and a polyoxyethylene polyoxypropylene ether block copolymer coupled to each other through an amide bond.
[0005] Preferably, the chemokine is MCP-1 polypeptide, the polyoxyethylene polyoxypropylene ether block copolymer is poloxamer, and the amide bond is formed by condensation of the amino group of the MCP-1 polypeptide and the terminal modified carboxyl group of the poloxamer.
[0006] Preferably, the amino acid sequence of the MCP-1 is as shown in SEQ ID No. 1, and the poloxamer is PluronicF127.
[0007] The drug delivery system of the present invention uses Pluronic F127 nanoparticles as the basic structure, the surface of which is carboxylated and then coupled with the targeting peptide MCP-1 for subsequent loading of tumor chemotherapy drug DOX. The effective ingredients are: Pluronic F127 86.5%-92%, MCP-1 7-12%, and DOX 1%-1.5%.
[0008] In order to obtain the above-mentioned macrophage targeted delivery vector, the present invention provides a method for preparing the vector, comprising the following steps:
[0009] (1) Carboxylating the surface of the polyoxyethylene polyoxypropylene ether block copolymer;
[0010] (2) dissolving the carboxylated polyoxyethylene polyoxypropylene ether block copolymer and adding EDC / NHS to obtain a first solution;
[0011] (3) adding the chemokine to the first solution to perform a coupling reaction to obtain a first product;
[0012] (4) The first product is dialyzed and then freeze-dried to obtain a macrophage targeted delivery vector.
[0013] Preferably, in step (1), the method of carboxylation treatment is: dissolving the polyoxyethylene polyoxypropylene ether block copolymer, succinic anhydride, 4-dimethylaminopyridine and triethylamine in 400 mL of 1,4-dioxane in a mass ratio of 100:1:1:1, stirring at 25°C for 24 hours, removing 1,4-dioxane by reduced pressure evaporation to obtain a residue, adding a sufficient amount of glacial ether to the obtained residue and slowly stirring to generate a precipitate, collecting the generated precipitate by filtration and repeatedly washing three to five times, and drying the obtained white solid to obtain a carboxylated polyoxyethylene polyoxypropylene ether block copolymer.
[0014] Preferably, in step (2), the solvent for dissolving the carboxylated polyoxyethylene polyoxypropylene ether block copolymer is ultrapure water; EDC / NHS is added to a final concentration of 0.001-0.01 mol / L, and the content of the polyoxyethylene polyoxypropylene ether block copolymer in the first solution is 50-70 g / L. EDC / NHS is a mixture of EDC and NHS, wherein the molar ratio of DEC to NHS is 1:1-3.
[0015] Preferably, in step (3), the solid-liquid ratio of the chemokine to the first solution is 0.0001-0.0005 g / mL; the coupling reaction conditions are stirring the reaction at 20-25°C for 24-48 hours; in step (4), the dialysis method is to place the first product in a dialysis bag with a molecular weight of 2000 and dialyze it for 24-48 hours.
[0016] The present invention further applies the above macrophage targeted delivery vector to the preparation of anti-tumor targeted drugs.
[0017] Specifically, the method for preparing an anti-tumor targeted drug using the above-mentioned macrophage targeted delivery vector comprises the following steps:
[0018] (1) dissolving the macrophage targeted delivery vector in an aqueous solution of a chemotherapeutic drug to obtain a micellar solution;
[0019] (2) The micelle solution is dialyzed to obtain the anti-tumor targeted drug.
[0020] Preferably, in step (1), the chemotherapeutic drug aqueous solution is an aqueous solution of doxorubicin, and the concentration of the macrophage targeted delivery carrier in the micelle solution is 10-40 mg / mL; in step (2), the dialysis method is to transfer the micelle solution into a dialysis bag with a molecular weight of 500 and dialyze for 24-48 hours; and the tumor includes non-small cell lung cancer.
[0021] In some embodiments, the concentration of the aqueous solution of doxorubicin is 300-700 μg / mL. The non-small cell lung cancer cell line is NCI-H1299.
[0022] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:
[0023] (1) The anti-tumor drug provided by the present invention is simple to synthesize, has good biocompatibility, can recognize macrophage surface receptors and be delivered to the tumor site by macrophages, has the advantages of good stability, tumor microenvironment response, and targeting the tumor area, and can enhance the tumor treatment effect under the same amount of drug.
[0024] (2) The present invention used NCI-H1299 as the research object and evaluated the in vitro anti-tumor effect of DOX@MPF127-MCP-1. The results showed that DOX@MPF127-MCP-1 could be taken up by NCI-H1299 cells and had a certain killing effect.
[0025] (3) In the established animal experimental model, DOX@MPF127-MCP-1 combined with macrophages showed a good tumor targeting effect. The in vivo IVIS experimental results showed that macrophages and DOX@MPF127-MCP-1 could bind and aggregate at the tumor site in vivo, targeting the tumor and showing good experimental results. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 It is the high performance liquid chromatography and high performance liquid chromatography-mass spectrometry of MCP-1 in the present invention;
[0027] Figure 2 is the infrared spectrum of MPF127 prepared in Example 1;
[0028] Figure 3 is the infrared spectrum of MPF127-MCP-1 prepared in Example 1;
[0029] Figure 4 is the XPS spectrum of MPF127-MCP-1 prepared in Example 1;
[0030] Figure 5 is the EDS spectrum of MPF127-MCP-1 prepared in Example 1;
[0031] Figure 6 It is the ultraviolet and infrared spectra of DOX@MPF127-MCP-1 nanoparticles prepared in Example 2;
[0032] Figure 7 are scanning electron microscopy and transmission electron microscopy images of DOX@MPF127-MCP-1 nanoparticles prepared in Example 2;
[0033] Figure 8 is a statistical diagram of the cytotoxic effect of DOX@MPF127-MCP-1 nanoparticles prepared in Example 2;
[0034] Fig. 9 This is a diagram showing the cellular uptake effect of DOX@MPF127-MCP-1 nanoparticles prepared in Example 2;
[0035] Fig.10 It is a cell migration effect diagram of the present invention;
[0036] Fig.11 This is a diagram of the in vivo targeting effect of DOX@MPF127-MCP-1 nanoparticles prepared in Example 2. DETAILED DESCRIPTION
[0037] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.
[0038] Example 1: A chemokine MCP-1 polypeptide, the amino acid sequence of which is shown in SEQ ID No. 1: CYNFTNRKISVQRLASYRRITSSK.
[0039] The MCP-1 polypeptide was prepared by conventional solid phase synthesis. The purity of the obtained MCP-1 polypeptide was determined by liquid chromatography (HPLC) and the molecular weight was determined by mass spectrometry. Figure 1 shown.
[0040] Figure 1 The HPLC chromatogram and HPLC-MS / MS of the MCP-1 targeting peptide of the present application are analyzed by C18 reverse chromatographic column. The retention time of the targeting peptide in the C18 column is about 13.175min. It is a single elution peak in HPLC with high purity, which meets the needs of subsequent experiments. The theoretical molecular weight of the peptide is 2892.36. The mass spectrometry analysis shows that the charge-to-mass ratio of its fragment ion peak [M+2H] 2+ 、[M+3H] 3+ 、[M+4H] 4+、[M+5H] 5+ 、[M+6H] 6+ This corresponds to the mass spectrometry results of 1447.15, 965.1, 724.1, 579.45, and 483.05, indicating that the peptide was successfully synthesized.
[0041] The macrophage targeted delivery vector was prepared using the chemokine MCP-1 polypeptide, and the method is as follows:
[0042] (1) Carboxylation treatment of the surface of Pluronic F127: Pluronic F127, succinic anhydride, 4-dimethylaminopyridine and triethylamine were dissolved in 400 mL of 1,4-dioxane at a mass ratio of 100:1:1:1, and stirred at 25°C for 24 hours. The 1,4-dioxane was removed by evaporation under reduced pressure to obtain a residue. A sufficient amount of glacial ether was added to the residue and stirred slowly to generate a precipitate. The precipitate was collected by filtration and washed repeatedly for three to five times. The obtained white solid was dried to obtain a carboxylated polyoxyethylene polyoxypropylene ether block copolymer. The properties of the modified Pluronic F127 were measured by infrared spectroscopy. The results are as follows: Figure 2 shown. Figure 2 The infrared spectrum of the modified Pluronic F127 (MPF127) shows that compared with the unmodified Pluronic F127 (PF127), the modified Pluronic F127 under the action of succinic anhydride has a peak at 1734.2 cm -1 The characteristic peak of carbonyl group appeared at , which successfully verified that the hydroxyl group of PF127 was modified into carboxyl group.
[0043] (2) Dissolve carboxylated Pluronic F127 in ultrapure water, add EDC / NHS to a final concentration of 0.005 mol / L to obtain a first solution; the content of Pluronic F127 in the first solution is 60 g / L. EDC is 1-ethyl-(3-dimethylaminopropyl)carbodiimide; NHS is N-hydroxysuccinimide, and the molar ratio of EDC to NHS in EDC / NHS is 1:1.
[0044] MCP-1 was amidated and coupled with modified Pluronic F127 (MPF127) using the EDC / NHS method. The amide bond was formed by condensation of the amino group of the MCP-1 polypeptide and the carboxyl group modified at the end of the poloxamer. The properties of the coupled MPF127-MCP-1 were detected by infrared spectra, XPS and EDS. The results are as follows: Figure 3 shown.
[0045] Figure 3-5 It is the infrared spectrum, XPS spectrum and EDS element spectrum of this application, Figure 3The infrared spectrum in the figure shows that the amide I (C=O) at 1673 cm belonging to MCP-1 was detected in MPM. -1 and 1532 cm of amide II (NH) and (CN) -1 ,1204cm -1 and 1139cm -1 The peaks at 2887 cm-1 and 2887 cm-2 from both (CH) and (C=O) of MPF127 are shown. -1 and 1734cm -1 Peak value.
[0046] Figure 4 The full XPS scan in the image shows all elements (C / N / O / S) of MPM. The XPS spectra of C1s (286.04eV, 288.94eV) and O1s (532.44eV, 531.44eV) were analyzed to obtain the characteristic peaks of COC and OC=O. The N1s spectrum and S2p spectrum successfully verified the existence of amide bond N-(C=O)- (399.94eV) and the presence of S element CS (163.54eV) in the polypeptide, thus successfully verifying the successful synthesis of MPM.
[0047] Figure 5 The EDS in the sample showed that the elements of MPM were C, O, N, and S. The proportions of C and O in MPM were 81.69% and 12.98%, respectively. The only S element in MCP-1 accounted for about 5.33% in MPM. The elemental composition in EDS was consistent with that in MCP-1 and PF127, and corresponded to the XPS spectrum, verifying the successful synthesis of MPM.
[0048] (3) adding the chemokine to the first solution at a solid-liquid ratio of 0.0001 g / mL, stirring the reaction at 25° C. for 36 h to perform a coupling reaction to obtain a first product;
[0049] (4) The first product was placed in a dialysis bag with a molecular weight of 2000 and dialyzed for 36 hours, followed by freeze-drying to obtain the macrophage targeted delivery vector MPF127-MCP-1.
[0050] Example 2: The MPF127-MCP-1 prepared in Example 1 was used to prepare an anti-tumor targeted drug, and the method was as follows:
[0051] (1) Dissolve MPF127-MCP-1 in an aqueous solution of doxorubicin at a concentration of 500 μg / mL to obtain a micellar solution; the concentration of MPF127-MCP-1 in the micellar solution is 25 mg / mL.
[0052] (2) The micellar solution was transferred into a dialysis bag with a molecular weight cutoff of 500 and dialyzed for 36 h to obtain the anti-tumor targeted drug DOX@MPF127-MCP-1, whose active ingredients are: PF127 90%, MCP-1 8.7%, and DOX 1.3%.
[0053] The present invention mixes MPF127-MCP-1 with the chemotherapy drug doxorubicin (DOX) to form DOX@MPF127-MCP-1. The nanomaterial loaded with DOX is detected by ultraviolet spectrum, infrared spectrum and electron microscope. The results are as follows Figure 6 , Figure 7 shown.
[0054] Figure 6 The left picture in the middle is the UV spectrum of DOX@MPF127-MCP-1, and the right picture is the infrared spectrum of DOX@MPF127-MCP-1. The UV spectrum shows that DOX@MPF127-MCP-1 has a certain blue shift at the 275nm peak of MCP-1 and the 280nm peak of MPF127. At the same time, the peak of DOX@MPF127-MCP-1 loaded with DOX at 480nm has an obvious red shift, proving that DOX@MPF127-MCP-1 was successfully prepared.
[0055] The synthesis of the designed DMPM was further explained by Fourier transform infrared spectroscopy. The 3526 cm -1 、3330cm -1 (OH), 1617cm -1 (C=O), 1617cm -1 (C=O) and 991cm -1 The characteristic peak of DOX at (NH) indicated that MPF127-MCP-1 had successfully encapsulated DOX to form DMPM nanoparticles.
[0056] Figure 7 It is the scanning electron microscopy and transmission electron microscopy of DOX@MPF127-MCP-1 of the present application. From the SEM image, it can be seen that DOX@MPF127-MCP-1 is a uniform sphere with an average diameter of about 150nm. Subsequently, transmission electron microscopy characterization was carried out. From the TEM image, similar conclusions can be drawn as in the SEM, but the particle size has changed slightly, which is about 100nm.
[0057] Embodiment 3: The rest is the same as Embodiment 1, except that:
[0058] In step (2), ultrapure water is used to dissolve carboxylated Pluronic F127, and EDC / NHS is added to a final concentration of 0.01 mol / L to obtain a first solution; the content of Pluronic F127 in the first solution is 50 g / L. The molar ratio of EDC to NHS in EDC / NHS is 1:3.
[0059] In step (3), the MCP-1 polypeptide is added to the first solution at a material-liquid ratio of 0.0005 g / mL, and the reaction is stirred at 25° C. for 24 h to perform a coupling reaction;
[0060] In step (4), the first product is placed in a dialysis bag with a molecular weight of 2000 and dialyzed for 24 hours.
[0061] Embodiment 4: The rest is the same as Embodiment 1, except that:
[0062] In step (2), ultrapure water is used to dissolve carboxylated Pluronic F127, and EDC / NHS is added to a final concentration of 0.001 mol / L to obtain a first solution; the content of Pluronic F127 in the first solution is 70 g / L.
[0063] In step (3), the MCP-1 polypeptide is added to the first solution at a solid-liquid ratio of 0.0001 g / mL, and the reaction is stirred at 25° C. for 48 hours to perform a coupling reaction;
[0064] In step (4), the first product is placed in a dialysis bag with a molecular weight of 2000 and dialyzed for 48 hours.
[0065] Embodiment 5: The rest is the same as Embodiment 2, except that:
[0066] (1) The MPF127-MCP-1 prepared in Example 3 was dissolved in an aqueous solution of doxorubicin having a concentration of 700 μg / mL to obtain a micellar solution; the concentration of MPF127-MCP-1 in the micellar solution was 10 mg / mL.
[0067] (2) The micellar solution was transferred into a dialysis bag with a molecular weight cut-off of 500 and dialyzed for 24 h.
[0068] The effective ingredients in the final product are: PF127 86.5%, MCP-1 12%, and DOX 1.5%.
[0069] Embodiment 6: The rest is the same as Embodiment 2, except that:
[0070] (1) The MPF127-MCP-1 prepared in Example 4 was dissolved in an aqueous solution of doxorubicin having a concentration of 300 μg / mL to obtain a micellar solution; the concentration of MPF127-MCP-1 in the micellar solution was 40 mg / mL.
[0071] (2) The micellar solution was transferred into a dialysis bag with a molecular weight cut-off of 500 and dialyzed for 48 h.
[0072] The effective ingredients in the final product are: PF127 92%, MCP-1 7%, and DOX 1%.
[0073] The DOX@MPF127-MCP-1 prepared in Example 2 was used in an inhibition test on NCI-H1299 tumor cells in the following manner:
[0074] The cell counting kit (CCK-8) method was used to detect the cytotoxicity of DOX and DOX@MPF127-MCP-1 to NCI-H1299 cells in vitro. PF127, MPF127, MCP-1, MPF127-MCP-1, DOX and DOX@MPF127-MCP-1 micelle samples with different concentrations (0-800 μg / mL) were prepared using the culture medium DMEM. NCI-H1299 cells were seeded in 96-well plates (1×10 6 After culturing for 24 hours, 100 μL of culture medium containing samples of different concentrations was added, and pure DMEM was used as a control. After incubation for 24 hours, the culture medium was removed, washed three times with PBS, and then mixed with 100 μL of culture medium containing 10% CCK-8 for 1 hour. The absorbance of the well plate at 450 nm was measured using an ELISA instrument and the cell viability (%) was calculated.
[0075] The results are as follows Figure 8 As shown in the figure, even at a high concentration of 800 μg / mL, NCI-H1299 cells in the PF127, MPF127, MCP-1 and MPF127-MCP-1 groups still maintained high cell viability. Both DOX@MPF127-MCP-1 and DOX showed significant anti-tumor ability at low concentrations. When the DMPM concentration was 800 μg / mL, the cell survival rate was only about 40%. At this time, the DOX concentration was 12 μg / mL, which showed higher anti-tumor ability than the same concentration of free DOX (cell survival rate was about 45%). According to the calculation, the IC of DOX@MPF127-MCP-1 50 About 9.15μg / mL.
[0076] The DOX@MPF127-MCP-1 prepared in Example 2 was used for the uptake test of NCI-H1299 tumor cells, and the method was as follows:
[0077] S1, NCI-H1299 cell samples (2×10 5Cells / well) were seeded in 6-well plates and cultured overnight, and then DOX@MPF127-MCP-1 (concentration of 15μg / mL) was added at different time intervals (0.5, 2, 6 and 12h), and pure DMEM was used as a control. After incubation, NCI-H1299 cells were fixed with 5% paraformaldehyde for 20min, stained with DAPI, and the nuclear morphology was observed under a fluorescence microscope.
[0078] S2, DMPM (DOX concentration of 15 μg / mL) was inoculated into NCI-H1299 cells and incubated for different times (0.5, 2, 6, and 12 h), then digested with EDTA-free trypsin and centrifuged, and then the fluorescence intensity of DOX@MPF127-MCP-1 was detected by flow cytometry.
[0079] The results are as follows Fig. 9 As shown. No fluorescence was observed in NCI-H1299 cells at 0h, and then the fluorescence intensity of DOX gradually increased with the extension of incubation time, reaching a high level at 12h. The flow cytometry results also showed the same trend. The fluorescence intensity of DOX@MPF127-MCP-1 in the cells increased with the extension of incubation time. The results of fluorescence semi-quantitative analysis showed that the average fluorescence intensity of the cells reached 37.58AU at 12h, showing that the NCI-H1299 cell nucleus had been completely invaded by DOX, indicating that DOX@MPF127-MCP-1 can be engulfed by NCI-H1299 cells within 12h and cause cell death. The above results further verified that DOX in DOX@MPF127-MCP-1 can be successfully released and DOX@MPF127-MCP-1 can be taken up by NCI-H1299 cells to inhibit tumor cell proliferation.
[0080] The DOX@MPF127-MCP-1 prepared in Example 2 was used for cell migration experiments on macrophages RAW264.7 and tumor cells NCI-H1299, and the method was as follows:
[0081] S1, cultured RAW264.7 cells were evenly inoculated on the surface of the migration membrane in the upper chamber of the cell migration 24-well plate (200 μL, 2×105 cells / well), cultured at 37°C, 5% CO2 for 24 hours, and then MPF127, MCP-1, MPM and DMPM were added to the culture medium in the lower chamber. After 24 hours of culture, the culture medium in the 24-well plate was removed, the migration membrane was gently washed with PBS, fixed with 5% paraformaldehyde for 20 minutes, gently washed three times, and then stained with 0.1% crystal violet for 15 minutes, and the migrating cells in the lower layer of the migration membrane were observed using a fluorescence microscope.
[0082] S2, cultured NCI-H1299 cells were evenly seeded in the lower chamber of a 24-well cell migration plate (2×105 cells / well) and cultured for 24 h, then RAW264.7 cells were evenly seeded on the migration membrane surface of the upper chamber of the cell migration 24-well plate (200 μL, 2×10 5 cells / well), and after culturing for 24 h, staining observation was performed according to the steps shown in S1.
[0083] S3, cultured NCI-H1299 cells were evenly seeded in the lower chamber of a 24-well cell migration plate (200 μL, 2×10 5 cells / well) and cultured for 24 h. At the same time, RAW264.7 cells were co-incubated with DOX@MPF127-MCP-1 at 37 °C and 5% CO2 for 24 h. Then, MA-RAW264.7 was digested and evenly inoculated on the surface of the migration membrane in the upper chamber of the cell migration 24-well plate (200 μL, 2×10 5 cells / well), and after culturing for 24 h, staining observation was performed according to the steps shown in S1.
[0084] The results are as follows Fig.10As shown, there were almost no migrating cells in the control group and MPF127 group, while the cells in the MCP-1, MPM, and DOX@MPF127-MCP-1 groups migrated significantly. Compared with the control group, the relative migration rates of MCP-1, MPM, and DOX@MPF127-MCP-1 reached 170%, 220%, and 210%, respectively. The results showed that MCP-1 could mediate the assembly of backpacks (MA-DOX@MPF127-MCP-1) by combining DOX@MPF127-MCP-1 with MA, and its MCP-1 modification on the surface of PF127 had the same effect. In addition, this result further proves that the interaction of the CCR2 / MCP-1 axis can be widely used in targeted delivery systems. The targeted homing ability of RAW264.7 and RAW264.7-DOX@MPF127-MCP-1 (MA-DOX@MPF127-MCP-1) on NCI-H1299 cells was further verified. First, only RAW264.7 cells were inoculated in the upper chamber, and the DMEM control group and NCI-H1299 cell group were inoculated in the lower chamber. The migrating cells in the NCI-H1299 cell group were more obvious than those in the control group, with a relative migration rate of 243%, which may be due to the fact that tumor cells can release chemokines and attract MA to the tumor area. Next, it was further studied whether MA-DOX@MPF127-MCP-1 can be recruited to the tumor area under in vitro chemotaxis. The control group and NCI-H1299 cell group were inoculated in the lower chamber, and RAW264.7-DOX@MPF127-MCP-1 was inoculated in the upper chamber. The homing targeting effect of MA-DOX@MPF127-MCP-1 was still observed, with a relative migration rate of about 220%. Although the relative mobility of RAW264.7 decreased compared with RAW264.7-DMPM, it may be related to the fact that the protein receptor of RAW264.7 was occupied by DOX@MPF127-MCP-1 and the interaction of CCR2 / MCP-1 axis of RAW264.7 was weakened. The results showed that MA may deliver NPs DOX@MPF127-MCP-1 into tumor cells through homing effect. Compared with the biomimetic membrane of MA, living MA as a backpack can more effectively deliver drugs to the tumor area and hardly cause immune rejection reaction of the body.
[0085] The tumor targeting activity of DOX@MPF127-MCP-1 prepared in Example 2 on tumor-bearing mice in vivo was determined as follows:
[0086] The NCI-H1299 cell model was used to study the tumor targeting of MA-DOX@MPF127-MCP-1 by monitoring the fluorescence distribution of Cy5-labeled DOX@MPF127-MCP-1 (Cy5-DOX@MPF127-MCP-1). 3Cy5-DOX@MPF127-MCP-1 was injected into the tail vein at a drug concentration of 200 μg / mL and a dosing volume of 200 μL, and IVIS imaging was performed at different time points (0.5, 1, 2, 4, 6, 8, 12, and 24 h). In addition, in order to explore the in vivo enrichment of DOX@MPF127-MCP-1 in tumors, nude mice were killed 24 h after the tail vein injection of Cy5-DOX@MPF127-MCP-1, and IVIS was used to image the main organs and tumor tissues such as the heart, liver, spleen, lung, and kidney. The fluorescence imaging data were analyzed using IVIS and Image-J software.
[0087] The results are as follows Fig.11 As shown in the figure, DOX@MPF127-MCP-1 first accumulates in the liver and kidney, and then gradually reaches the tumor area and accumulates. A small amount of fluorescence can be seen in the tumor area within 1 hour after Cy5-DOX@MPF127-MCP-1 injection, and quantitative analysis shows that the fluorescence accounts for 0.62%. Over time, the fluorescence in the liver and kidneys gradually weakened, while the fluorescence in the tumor began to increase. The fluorescence intensity of the tumor site increased from 2.76% at 2h to 67.16% at 12h, and remained at 58.58% at 24h, while the fluorescence intensity of the liver and kidney was lower at 24h. After 24h, the nude mice were killed by gas anesthesia, and the main organs and tumor tissues of the mice were collected for tissue fluorescence imaging. The results showed that the tumor tissue had the strongest fluorescence intensity, followed by the liver and kidney tissues. Quantitative analysis of the average fluorescence intensity of Cy5-DOX@MPF127-MCP-1 in the tumor was about 7.66×10 7 , followed by kidney tissue (7.07×10 7 ), the lowest is the heart (8.53×10 6 ), indicating that the material has less cardiotoxicity and can effectively reduce the cardiotoxicity of DOX. These results further indicate that under the mediation of the CCR2 / MCP-1 axis, DOX@MPF127-MCP-1 can actively bind to MA to assemble the MA-DOX@MPF127-MCP-1 backpack, thereby achieving active targeted drug delivery in vivo. MA-mediated drug-loaded nanosystems can accumulate in tumors and maintain for a certain period of time, which has a significant effect on tumor treatment.
[0088] Comparative Example 1: The rest is the same as Example 1 and Example 2, except that:
[0089] Pluronic F68 was used to replace Pluronic F127.
[0090] Nude mouse models bearing different tumor strains were established. Drug administration began on the fourth day after tumor implantation, and was administered once every three days through the tail vein. The drug concentration was 200 μg / mL, and the administration volume was 200 μL. The blank control group was given normal saline. After 21 days of tumor implantation, the tumor inhibition rates of the anti-tumor targeted drugs prepared in Examples 2, 5, 6 and Comparative Example 1 on different tumor strains were measured. The results are as follows:
[0091] Table 1 Effects of different types of poloxamers on antitumor efficacy
[0092]
[0093]
[0094] As can be seen from the results in Table 1, the therapeutic effect of the present invention on lung cancer is significantly better than that on breast cancer, liver cancer and colon cancer, and the inhibition rate of each tumor strain is significantly higher than that of Comparative Example 1, indicating that the type of poloxamer is more important for the overall efficacy of the drug.
Claims
1. A macrophage-targeted delivery vector, characterized in that: The invention comprises a chemokine and a polyoxyethylene polyoxypropylene ether block copolymer coupled to each other via an amide bond.
2. The macrophage-targeted delivery vector according to claim 1, characterized in that: The chemokine is MCP-1 polypeptide, the polyoxyethylene polyoxypropylene ether block copolymer is poloxamer, and the amide bond is formed by condensing the amino group of the MCP-1 polypeptide and the terminal modified carboxyl group of the poloxamer.
3. The macrophage-targeted delivery vector according to claim 2, characterized in that: The amino acid sequence of the MCP-1 is shown in SEQ ID No. 1, and the poloxamer is Pluronic F127.
4. The method for preparing the macrophage-targeted delivery vector according to any one of claims 1 to 3, characterized in that: The steps include: (1) Carboxylating the surface of the polyoxyethylene polyoxypropylene ether block copolymer; (2) dissolving the carboxylated polyoxyethylene polyoxypropylene ether block copolymer and adding EDC / NHS to obtain a first solution; (3) adding the chemokine to the first solution to perform a coupling reaction to obtain a first product; (4) The first product is dialyzed and then freeze-dried to obtain a macrophage-targeted delivery vector.
5. The method for preparing the macrophage-targeted delivery vector according to claim 4, characterized in that: In step (1), the method for carboxylation treatment is as follows: dissolving the polyoxyethylene polyoxypropylene ether block copolymer, succinic anhydride, 4-dimethylaminopyridine and triethylamine in 400 mL of 1,4-dioxane at a mass ratio of 100:1:1:1, stirring at 25°C for 24 hours, removing 1,4-dioxane by evaporation under reduced pressure to obtain a residue, adding sufficient glacial ether to the obtained residue and slowly stirring to generate a precipitate, collecting the generated precipitate by filtration and repeatedly washing three to five times, and drying the obtained white solid to obtain a carboxylated polyoxyethylene polyoxypropylene ether block copolymer.
6. The method for preparing the macrophage-targeted delivery vector according to claim 4, characterized in that: In step (2), the solvent for dissolving the carboxylated polyoxyethylene polyoxypropylene ether block copolymer is ultrapure water; EDC / NHS is added to a final concentration of 0.001-0.01 mol / L, and the content of the polyoxyethylene polyoxypropylene ether block copolymer in the first solution is 50-70 g / L.
7. The method for preparing the macrophage-targeted delivery vector according to claim 4, characterized in that: In step (3), the material-liquid ratio of the chemokine to the first solution is 0.0001-0.0005 g / mL; the coupling reaction conditions are stirring the reaction at 20-25°C for 24-48 hours; in step (4), the dialysis method is to place the first product in a dialysis bag with a molecular weight of 2000 and dialyze it for 24-48 hours.
8. Use of the macrophage-targeted delivery vector according to any one of claims 1 to 3 in the preparation of anti-tumor targeted drugs.
9. The use according to claim 9, characterized in that The steps include: (1) dissolving the macrophage-targeted delivery vector in an aqueous solution of a chemotherapy drug to obtain a micelle solution; (2) The micelle solution is dialyzed to obtain the anti-tumor targeted drug.
10. The use according to claim 9, characterized in that In step (1), the chemotherapeutic drug aqueous solution is an aqueous solution of doxorubicin, and the concentration of the macrophage-targeted delivery carrier in the micelle solution is 10-40 mg / mL; in step (2), the dialysis method is to transfer the micelle solution into a dialysis bag with a molecular weight of 500 and dialyze for 24-48 hours; the tumor includes non-small cell lung cancer.
Citation Information
Patent Citations
Macrophages membrane coated breast cancer targeted nanoparticles and preparation method thereof
CN109953972A
MCP-1 delivery system
WO2010025176A2
Cited By
Mesoporous nanomaterial coupled with CCR2 antibody as well as preparation method and application of mesoporous nanomaterial
CN121197432A
